NO20030729L - Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister - Google Patents

Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister

Info

Publication number
NO20030729L
NO20030729L NO20030729A NO20030729A NO20030729L NO 20030729 L NO20030729 L NO 20030729L NO 20030729 A NO20030729 A NO 20030729A NO 20030729 A NO20030729 A NO 20030729A NO 20030729 L NO20030729 L NO 20030729L
Authority
NO
Norway
Prior art keywords
alkyl
unsubstituted
oxazolyl
substituted
acid derivatives
Prior art date
Application number
NO20030729A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030729D0 (no
Inventor
Dawn Alisa Brooks
Alexander Glenn Godfrey
Sarah Beth Jones
James Ray Mccarthy
Christopher John Rito
Jr Leonard Larry Winneroski
Yanping Xu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20030729D0 publication Critical patent/NO20030729D0/no
Publication of NO20030729L publication Critical patent/NO20030729L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20030729A 2000-08-23 2003-02-14 Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister NO20030729L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
PCT/US2001/022616 WO2002016331A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (2)

Publication Number Publication Date
NO20030729D0 NO20030729D0 (no) 2003-02-14
NO20030729L true NO20030729L (no) 2003-04-02

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030729A NO20030729L (no) 2000-08-23 2003-02-14 Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister

Country Status (26)

Country Link
US (2) US6930120B2 (enExample)
EP (1) EP1313716B1 (enExample)
JP (1) JP2004506721A (enExample)
KR (1) KR20030027054A (enExample)
CN (1) CN1471517A (enExample)
AT (1) ATE361283T1 (enExample)
AU (1) AU2001284659A1 (enExample)
BR (1) BR0113409A (enExample)
CA (1) CA2418104A1 (enExample)
CY (1) CY1107679T1 (enExample)
CZ (1) CZ2003482A3 (enExample)
DE (1) DE60128239T2 (enExample)
DK (1) DK1313716T3 (enExample)
EA (1) EA200300286A1 (enExample)
EC (1) ECSP034504A (enExample)
ES (1) ES2286137T3 (enExample)
HU (1) HUP0300857A3 (enExample)
IL (1) IL154110A0 (enExample)
MX (1) MXPA03001558A (enExample)
NO (1) NO20030729L (enExample)
NZ (1) NZ523804A (enExample)
PL (1) PL360744A1 (enExample)
PT (1) PT1313716E (enExample)
SK (1) SK1872003A3 (enExample)
WO (1) WO2002016331A1 (enExample)
ZA (1) ZA200300570B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001284660A1 (en) * 2000-08-23 2002-03-04 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
US6982278B2 (en) 2000-08-23 2006-01-03 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
PL208074B1 (pl) 2001-05-15 2011-03-31 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
RU2295520C2 (ru) 2002-07-03 2007-03-20 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ОКСАЗОЛА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ СЕНСИБИЛИЗАТОРОВ ИНСУЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВИРУЮЩИМ ДЕЙСТВИЕМ В ОТНОШЕНИИ PRARα И/ИЛИ PRARγ
DK1537091T3 (da) * 2002-08-30 2010-11-08 Hoffmann La Roche Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
MXPA05002704A (es) 2002-09-12 2005-05-05 Hoffmann La Roche Compuestos de acido n-sustituido-1h-indol-5-propionico como agonistas de los receptores activados proliferadores de peroxisomas (ppar) utiles para el tratamiento de diabetes.
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
ES2295692T3 (es) * 2002-11-08 2008-04-16 F. Hoffmann-La Roche Ag Nuevos derivados de 4-alcoxioxazol sustituido como agonistas de ppar.
DE60323130D1 (de) 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
ATE350369T1 (de) 2003-08-20 2007-01-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids
US20070293423A1 (en) * 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
WO2006057448A1 (ja) * 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited アリールアルカン酸誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
SK21099A3 (en) * 1996-08-19 2000-05-16 Japan Tobacco Inc Propionic acid derivatives and applications thereof
US6506757B1 (en) 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
US6982278B2 (en) 2000-08-23 2006-01-03 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
AU2001284660A1 (en) * 2000-08-23 2002-03-04 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
EP1313716A1 (en) 2003-05-28
CY1107679T1 (el) 2013-04-18
US20050245584A1 (en) 2005-11-03
NO20030729D0 (no) 2003-02-14
US6930120B2 (en) 2005-08-16
DE60128239D1 (de) 2007-06-14
ZA200300570B (en) 2004-04-21
DE60128239T2 (de) 2008-01-10
BR0113409A (pt) 2003-07-01
MXPA03001558A (es) 2003-06-06
CA2418104A1 (en) 2002-02-28
DK1313716T3 (da) 2007-08-27
ES2286137T3 (es) 2007-12-01
SK1872003A3 (en) 2003-07-01
AU2001284659A1 (en) 2002-03-04
ATE361283T1 (de) 2007-05-15
KR20030027054A (ko) 2003-04-03
US7345070B2 (en) 2008-03-18
JP2004506721A (ja) 2004-03-04
CZ2003482A3 (cs) 2003-05-14
HUP0300857A3 (en) 2007-03-28
ECSP034504A (es) 2003-04-25
WO2002016331A1 (en) 2002-02-28
EP1313716B1 (en) 2007-05-02
HUP0300857A2 (hu) 2003-10-28
IL154110A0 (en) 2003-07-31
PT1313716E (pt) 2007-07-11
NZ523804A (en) 2004-09-24
PL360744A1 (en) 2004-09-20
US20040097590A1 (en) 2004-05-20
CN1471517A (zh) 2004-01-28
EA200300286A1 (ru) 2003-08-28

Similar Documents

Publication Publication Date Title
NO20030729L (no) Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister
AU2001284658A1 (en) Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
PT96255A (pt) Processo para a preparacao de novos derivados da 1-naftil-piperazina
SE423812B (sv) Forfarande for framstellning av terapeutiskt aktiva derivat av azetidin-2-karboxylsyra, prolin och pipekolinsyra
DK0540051T3 (da) Aromatiske amidinderivater og salte deraf
AR037898A1 (es) Compuesto de benzamida, uso de un compuesto de benzamida en la fabricacion de un medicamento, proceso para su preparacion y composicion farmaceutica que lo comprende
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
NO991957D0 (no) Nye benzotiofen, benzofuran og indolforbindelser, en fremgangsmÕte ved deres fremstilling og farmas°ytiske sammensetninger inneholdende dem
CO5640098A2 (es) Acidos biariloximetilaren-carboxilicos
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
WO2002028844A1 (en) Thiazole or oxazole derivatives
MXPA02011352A (es) Nuevos derivados de benzofurano.
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
SE8006365L (sv) Cyklohexankarboxylsyraderivat
NO994340L (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler samt nye forbindelser til anvendelse for dette formÕl
NO994209L (no) Fremgangsmaate for fremstilling av 2-ÄÄ(2-pyridinyl)metylÜsulfinylÜ-1H-benzimidazoler og nye forbindelser til anvendelse for dette formaal
NO20051089L (no) Bredspektrede 2-amino-benzotiazol-sulfonamid-HIV-proteaseinhibitorer
NO20074738L (no) Aktivator for peroksisom-proliferator som aktiverer reseptor delta
DK1559714T3 (da) Fremgangsmåde til fremstilling af 2-alkyl-3-aminothiophenderivater og 3-aminothiophenderivater
DK1023898T3 (da) Cyanoindoler som serotonin-genoptagningsinhibitorer og som 5-HT2c-receptorligander
WO2007068815A3 (fr) Derives heterocycliques, leur preparation et leur application en therapeutique.
NO20003431D0 (no) Nye metalloproteaseinhibitorer, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
AR008920A1 (es) Proceso para la preparacion de los derivados de 2-amino-2-imidaxolina, guanidina, y 2-amino-3,4,5,6-tetrahidropiridimina
ES2087917T3 (es) Derivados de 1,2-dihidro-2-oxo-quinoxalinas, su preparacion y su aplicacion en terapeutica.
AU532634B2 (en) Thiazolyl derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application